GTCR Buys Zentiva: $4.8 Billion Pharma Deal
Update: 2025-09-11
Description
A $4.8 billion shakeup in the European pharmaceutical world! US private equity firm GTCR is set to acquire Zentiva, a major generic drug maker, from Advent International. What does this mean for drug prices, job growth, and the future of generic medicine in Europe? Find out how this massive deal could impact you.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
